XONDROITIN-AKOS (Capsules)

Active material: Chondroitin sulfate
When ATH: M01AX25
CCF: Preparation, regulates the metabolism of the cartilage
ICD-10 codes (testimony): M15, M42
When CSF: 16.05.01
Manufacturer: Synthesis of (Russia)

PHARMACEUTICAL FORM, COMPOSITION AND PACKAGING

Capsules hard gelatin, size №1, with blue lid and blue body; contents of capsules – powder white or white with a slightly yellowish tint.

Excipients: lactose, calcium stearate.

Capsule: Titanium dioxide, dye azorubin, carmine dye (Ponceau 4R), patented blue dye (patent blue V), dye Brilliant Black (black diamond BN), metilparagidroksiʙenzoat (metilgidroksiʙenzoat), propilparagidroksibenzoat (propyl), acetic acid, gelatin.

10 PC. – packings Valium planimetric (2) – packs cardboard.
10 PC. – packings Valium planimetric (5) – packs cardboard.
10 PC. – packings Valium planimetric (6) – packs cardboard.

Pharmacological action

The stimulator of regeneration of cartilage (chondroprotector). The high mucopolysaccharide, derived from bovine trachea cartilage. It affects the metabolic processes in hyaline and fibrocartilage, reduces degenerative changes in the cartilage tissue of the joints, stimulates the biosynthesis of glycosaminoglycans. Promotes the regeneration of the cartilaginous surfaces of the joints and articular bag, increases the production of synovial fluid. It slows bone resorption and reduces calcium loss, accelerates bone regeneration.

Treatment with the drug reduces pain and improves the mobility of the affected joints.. The therapeutic effect lasts a long time after the end of the course of treatment.

Pharmacokinetics

Absorption and distribution

After taking the drug inside more 70% chondroitin sulfate is absorbed from the gastrointestinal tract.

After a single oral administration at an average therapeutic dose C_max plasma levels achieved after 3-4 no, synovial fluid – through 4-5 no. Bioavailability is 13%.

Chondroitin sulfate is accumulated in the synovial fluid.

Deduction

Report the news.

Testimony

Degenerative diseases of the joints and spine:

- Osteoarthritis;

- Osteochondrosis.

Dosage regimen

The drug is taken orally, during or after a meal, drinking at least 1/2 cup water.

Adults and adolescents aged 15 and older administered at a dose of 1 g / day – by 2 capsules 2 times / day. The recommended duration of treatment is the initial 6 months. The period of action of the drug after its withdrawal – 3-5 months depending on the location and stage of the disease. The doctor sets the duration of repeated courses of treatment individually.

Side effect

From the digestive system: rarely – nausea, vomiting.

Allergic reactions: rarely – hives, each erythema, itching.

Contraindications

- Children up to age 15 years;

- Hypersensitivity to the drug;

FROM caution the drug should be used in patients with bleeding and a tendency to bleed, with thrombophlebitis.

Pregnancy and lactation

Not recommended to prescribe the drug during pregnancy and lactation (breast-feeding) due to the lack of sufficient clinical data.

Cautions

Contraindicated for use in children younger 15 years due to the lack of accurate data on the efficacy and safety of the drug in this category of patients.

Overdose

Symptoms: rarely – nausea, vomiting, diarrhea; Propafenone in extremely high doses (more 3 g / day) possible hemorrhagic rash.

Treatment: symptomatic therapy.

Drug Interactions

With the simultaneous use of the drug Chondroitin-AKOS with other drugs, it is possible to enhance the action of indirect anticoagulants, antiagregantov, fibrinolitikov.

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

The drug should be stored out of reach of children, dry, protected from light at a temperature not exceeding 20 ° С. Shelf life – 3 year.